



M

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/04, 48/00, C07K 7/08, C12N 15/11	A1	(11) International Publication Number: WO 99/45944 (43) International Publication Date: 16 September 1999 (16.09.99)
(21) International Application Number: PCT/US99/05250 (22) International Filing Date: 11 March 1999 (11.03.99) (30) Priority Data: 09/041,886 12 March 1998 (12.03.98) US (71) Applicant: THE BURNHAM INSTITUTE [US/US]; 10901 North Torrey Pines Road, La Jolla, CA 92037 (US). (72) Inventors: BREDESEN, Dale, E.; P.O. Box 7045, Rancho Santa Fe, CA 92067 (US). RABIZADEH, Shahrooz; 526 Camino Del Mar, Del Mar, CA 92014 (US). (74) Agents: FAN, Calvin, A. et al.; Campbell & Flores LLP, Suite 700, 4370 La Jolla Village Drive, San Diego, CA 92122 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: PROAPOPTOTIC PEPTIDES, DEPENDENCE POLYPEPTIDES AND METHODS OF USE (57) Abstract The present invention provides substantially pure proapoptotic dependence peptides. The peptides consist substantially of the sequence of an active dependence domain selected from the group of dependence polypeptides consisting of p75 ^{NTR} , androgen receptor, DCC, huntingtin polypeptide, Machado-Joseph disease gene product, SCA1, SCA2, SCA6 and atrophin-1 polypeptide. Substantially pure proapoptotic dependence peptides include SATLDALLAALRRI (SEQ ID NO:3), Q14 (SEQ ID NO:7), SATLDALLAALGGI (SEQ ID NO:4), SATLDALLAALRGI (SEQ ID NO:5), SATLQALLAALRRI (SEQ ID NO:6), tat-GG-SATLDALLAALRRI (SEQ ID NO:37) and tat-GG-Q14 (SEQ ID NO:36). The invention also provides a method of increasing cell survival. The method consists of inhibiting the function of an active proapoptotic dependence domain. A method of increasing cell survival consisting of preventing or reducing the rate of formation of an active proapoptotic dependence domain is also provided. The invention further provides a method of identifying compounds which prevent or inhibit apoptosis. The method consists essentially of administering a test compound to a cell undergoing dependence domain mediated apoptosis, and determining whether the compound increases cell survival. A method of reducing the severity of a proapoptotic dependence domain mediated pathological condition is also provided. The method consists of inhibiting the function of an active dependence domain. Additionally provided is a method of reducing the severity of a pathological condition mediated by unregulated cell growth. The method consists of cytoplasmically administering a proapoptotic dependence peptide.		